Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Eli Lilly has recently unveiled significant advancements across its product line, including promising results from the BRAVE-AA-PEDS study on adolescents ... to build four new manufacturing ...

the company's decision to construct new manufacturing sites in the U.S., creating thousands of jobs, indicates an aggressive expansion strategy. Such advances likely contributed to Eli Lilly's ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

An estimated 6 to 17 percent of children have sleep-disordered breathing, ranging from snoring to sleep apnea, which can cause behavioral, neurocognitive, cardiovascular, and cardiometabolic issues. A ...

Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly ... an injectable under study that contains GLP-1 ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...